ZHEJIANG ANGLIKANG PHARMACEUTICAL CO.,LTD.

Zhejiang AngLiKang Pharmaceutical CO.,LTD.

002940

CNE100003GC2

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-27 pm EDT			5-day change	1st Jan Change
17.54 ^CNY	-2.56%		-0.85%	-19.21%

Apr. 26	Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 02	Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023.	CI

Zhejiang Anglikang Pharmaceutical Co.,LTD. Approves Management Appointments

January 06, 2021 at 02:37 pm EST

Zhejiang AngLiKang Pharmaceutical CO.,LTD. at its EGM held on January 5, 2021 approved appointment of Mo Weimin and Zhao Xiufang as independent directors. The company also appointed Li Ling as non-employee supervisor.

Latest news about Zhejiang AngLiKang Pharmaceutical CO.,LTD.

Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023.	Apr. 01	CI
Anglikang Pharmaceutical Signs Licensing Deal for Affinity Biomedical's Tumor Drug	Feb. 06	MT
Anglikang Pharma's Unit Gets Nod for Enalapril Maleate Tablets	Jan. 29	MT
Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023.	Jan. 02	CI
Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023.	23-10-10	CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. announces an Equity Buyback for CNY 60 million worth of its shares.	23-08-30	CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. authorizes a Buyback Plan.	23-08-29	CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24	CI
Anglikang Pharmaceutical's Unit Gets Veterinary, GMP Certificates	23-08-17	MT
Anglikang Pharmaceutical Registers Metabolism Disorder Drug in China	23-06-27	MT
Anglikang Pharma Obtains Nod to Market Sevoflurane Active Pharma Ingredient in China	23-06-16	MT
Zhejiang Anglikang Pharmaceutical Co.,Ltd. Announces Cash Dividend on A Shares for the Year 2022, Payable on May 19, 2023	23-05-12	CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Approves Final Cash Dividend for 2022	23-04-24	CI
Anglikang Pharma Signs Five-Year Purchase Agreement With European Firm	23-04-06	MT
Zhejiang Anglikang Pharmaceutical Co.,Ltd. Proposes Final Cash Dividend for 2022	23-04-02	CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Anglikang Pharma’s Drug to Lower Hypertension Fails to Make It on China’s Drug Procurement List	23-03-30	MT
Chinese Shares End Mixed; Anglikang Pharma Slides 8% on 191 Million Yuan M&A Plan	23-03-24	MT
Zhejiang Anglikang Pharma to Boost Stake in Local Biopharma Firm to 62% For 191 Million Yuan	23-03-24	MT
Zhejiang AngLiKang Pharmaceutical CO.,LTD. completed the acquisition of an additional 38.22% stake in Hunan Kerey Pharmaceutical Co., Ltd. from Gan Hongxing, Hu Aiguo, Yang Xiangxin and Xie Laibin.	23-03-21	CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-23	CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. signed a share transfer agreement to acquire an additional 38.22% stake in Hunan Kerey Pharmaceutical Co., Ltd. from Gan Hongxing, Hu Aiguo, Yang Xiangxin and Xie Laibin for approximately CNY 191.3 million.	22-10-11	CI
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-29	CI

Chart Zhejiang AngLiKang Pharmaceutical CO.,LTD.

Duration

Period

Chart Zhejiang AngLiKang Pharmaceutical CO.,LTD.

More charts

Company Profile

Zhejiang AngLiKang Pharmaceutical CO.,LTD. is a China-based company principally engaged in the research, development, production and sales of chemical raw materials and preparations. The Company's products mainly include cephalosporin and penicillin series, anti-hypertension series, digestive system series, kidney disease series and others.

Sector

Pharmaceuticals

Calendar

2024-08-25 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ZHEJIANG ANGLIKANG PHARMACEUTICAL CO.,LTD.	-19.21%	478M
ELI LILLY AND COMPANY	+38.59%	727B
JOHNSON & JOHNSON	-7.89%	347B
MERCK & CO., INC.	+15.66%	319B
ABBVIE INC.	+0.24%	274B
ASTRAZENECA PLC	+13.47%	238B
NOVARTIS AG	+7.35%	204B
ROCHE HOLDING AG	-6.42%	203B
AMGEN INC.	+4.23%	161B
PFIZER, INC.	-1.70%	160B